Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05570552
Other study ID # PR-22057 (2U01TW010120-06)
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 20, 2023
Est. completion date June 2027

Study information

Verified date March 2024
Source International Centre for Diarrhoeal Disease Research, Bangladesh
Contact Rubhana Raqib, PhD
Phone +8802222277001-10
Email rubhana@icddrb.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Almost 3 billion people worldwide, including 89% people in Bangladesh, are exposed to harmful household air pollutants (HAP) emitted from combustion of biomass (wood, agricultural residue, cow dung, etc.) fuel use for cooking. While health risks associated with air-pollution have been reasonably well-studied in developed countries, there is little evidence on health benefits achievable by HAP reduction through clean fuel use, especially in low- and middle-income countries (LMICs). Earlier the investigators showed that Liquid Petroleum Gas (LPG) for 24 months, reduced personal PM2.5 exposure by 58.17 percent which induced novel changes in immune and inflammatory responses in the participants; however cardiopulmonary markers remained relatively stable in post-intervention assessment. In this study, the investigators aim to evaluate the effects of mobile phone based (mHealth) Behavioural Change Communication (BCC) intervention on adoption and exclusive use of LPG. The investigators also aimed to observe whether long-term effects of HAP reduction can impact the subclinical measures of cardio-vascular and pulmonary dysfunction and regulate innate and inflammatory immune function among women and children in semi-rural settings in Bangladesh. The investigators will also investigate the influence of exposure to HAP on antibody response to vaccines (adaptive immunity). The BCC intervention will be provided by conducting a large household level randomized controlled trial by educational intervention using mHealth based technology. In addition, the investigators will continue following the cohort and will conduct rigorous and repeated personalized (24 hours) and area (over 5 days) assessments of PM2.5 and black carbon (BC) exposure to examine the long-term effects of HAP reduction on subclinical measures of cardio-pulmonary and immune dysfunction including effect of HAP exposure on antibody response to vaccine.


Description:

Background: Almost 3 billion people worldwide, including 89% people in Bangladesh, are exposed to harmful household air pollutants (HAP) emitted from combustion of biomass fuel (wood, agricultural residue, cow dung, etc.) used for cooking. While health risks associated with air-pollution have been reasonably well-studied in developed countries, there is little evidence on health benefits achievable by HAP reduction through clean fuel use such as Liquid Petroleum Gas, especially in low- and middle-income countries (LMICs). Rationale: In the earlier GEOHealth (Round-I) study, the investigators have shown that LPG for 24 months, reduced personal PM2.5 exposure by 58.2 percent which induced novel changes in innate immune and inflammatory responses in women but the changes in chronic cardio-pulmonary markers were not prominent, most likely due to short duration of follow up and probably impact of ambient pollution. Moreover, sustained use of LPG could be challenging as earlier GEOHealth (Round-I) study provided the cook stove and supply of LPG free of cost. A post-completion screening showed >70% households continued using LPG albeit not exclusively. It is plausible that an intervention using mobile phone-based application can improve the exclusive use of LPG in the communities. Hypothesis: 1. The mobile phone based (mHealth) Behavioural Change Communication (BCC) intervention can be easily incorporated in Government policy that can promote adoption, and increase exclusive use of LPG in the communities. The long-term effect of HAP reduction can be associated with- 2. subclinical measures of cardio-vascular and pulmonary dysfunction. 3. balanced changes in innate/ inflammatory and adaptive immune function (vaccine response). Objectives: To evaluate 1. The effects of a scalable educational intervention (using mHealth application) on adoption and exclusive use of LPG. 2. The long-term effects of HAP reduction on subclinical measures of cardio-vascular and pulmonary dysfunction. 3. The long-term effects of HAP reduction on innate/ inflammatory immune function among women and children and to investigate the influence of HAP exposure on antibody response to vaccines (adaptive immunity). Methods: The investigators will conduct a large household level randomized controlled trial by educational intervention using mobile phone (mHealth) based technology. In addition, the investigators will continue following the cohort and will conduct rigorous and repeated personalized (24 hours) and area-wise (over 5 days) assessments of PM2.5 and black carbon (BC) exposure to examine the long-term effects of HAP reduction on subclinical measures of cardio-pulmonary and immune dysfunction including effect of HAP exposure on antibody response to vaccine. Outcome measures/variables: Personal and surrounding area PM2.5 and BC level will be measured at pre- and post-intervention. Lung function and lung pathology will be assessed through spirometry, Chest X-ray, and High-resolution Computed tomography of the chest (HRCT). Preclinical makers of cardiovascular diseases (CVD) will include blood pressure and EKG. Markers of metabolic dysfunction will be assesses by measuring HbA1c and fasting lipid profile. Immune function will be assessed by phenotyping of Immune cells, functional cytotoxic killer cells, oxidative stress of lymphocytes.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date June 2027
Est. primary completion date May 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 25 Years to 70 Years
Eligibility Inclusion Criteria: - Participants in the previous GEOHEALTH round-I study - Aged between 25 and 70 years - Live in biomass-using home with traditional stoves - Non-smoker and live with non-smokers - Exposed to <10 µg/L of water arsenic Exclusion Criteria: - Known to have immune related illness or taking any prescription medication (particularly those that suppress or enhance immune function) - Known to have any clinical events of CVD or lung disease, including stroke or coronary heart disease.

Study Design


Intervention

Behavioral:
mHealth based behavioral change communication intervention
We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.

Locations

Country Name City State
Bangladesh International Centre for Diarrhoeal Diseases Research, Bangladesh Dhaka

Sponsors (4)

Lead Sponsor Collaborator
International Centre for Diarrhoeal Disease Research, Bangladesh Mailman School of Public Health, Marquette University, University of Chicago

Country where clinical trial is conducted

Bangladesh, 

Outcome

Type Measure Description Time frame Safety issue
Primary Personal air pollution Measurement of personal air pollution (PM2.5 and BC level) by personal air pollution monitoring device Pre-intervention
Primary Personal air pollution Measurement of personal air pollution (PM2.5 and BC level) by personal air pollution monitoring device Two-year post intervention
Primary Ambient air pollution Measurement of ambient air pollution (PM2.5) by ambient air monitoring device Pre-intervention
Primary Ambient air pollution Measurement of ambient air pollution (PM2.5) by ambient air monitoring device Two-year post intervention
Primary Lung function assessment by spirometry Lung function assessment by spirometry Pre-intervention
Primary Lung function assessment by spirometry Lung function assessment by spirometry Two-year post intervention
Primary Assessment lung pathology by chest X-ray and High-resolution Computed tomography Lung pathology will be assessed by chest X-ray for all participants and high-resolution Computed tomography of the chest (HRCT) will be performed in selected participants. Pre-intervention
Primary Assessment lung pathology by chest X-ray and High-resolution Computed tomography Lung pathology will be assessed by chest X-ray for all participants and high-resolution Computed tomography of the chest (HRCT) will be performed in selected participants. Two-year post intervention
Primary Measurement of cardiovascular disease (CVD) markers by measuring blood pressure Preclinical markers of CVD assessment by blood pressure Pre-intervention
Primary Measurement of cardiovascular disease (CVD) markers by measuring blood pressure Preclinical markers of CVD assessment by blood pressure Two-year post intervention
Primary Measurement of cardiovascular disease (CVD) markers by performing EKG Preclinical markers of CVD assessment by EKG Pre-intervention
Primary Measurement of cardiovascular disease (CVD) markers by performing EKG Preclinical markers of CVD assessment by EKG Two-year post intervention
Primary Evaluation of metabolic markers (diabetes) in blood at baseline. Assessment of metabolic dysfunction by measuring HbA1c Pre-intervention
Primary Evaluation of metabolic markers (diabetes) in blood after intervention. Assessment of metabolic dysfunction by measuring HbA1c Two-year post intervention
Primary Evaluation of metabolic markers (CVD) in blood. Assessment of metabolic dysfunction by measuring fasting lipid profile. Pre-intervention
Primary Evaluation of metabolic markers (CVD) in blood. Assessment of metabolic dysfunction by measuring fasting lipid profile. Two-year post intervention
Primary Assessment of immune function in blood cells Immune function will be assessed by phenotyping using flowcytometry Pre-intervention
Primary Assessment of immune function in blood cells Immune function will be assessed by phenotyping using flowcytometry Two-year post intervention
See also
  Status Clinical Trial Phase
Completed NCT01545219 - A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers N/A
Completed NCT03201068 - Probiotic Supplement and Microbiome, Immune System and Metabolic Syndrome N/A
Completed NCT04960878 - The Effect of Synbiotics on the Upper Respiratory Tract Infection N/A
Completed NCT01235390 - Effects of the Consumption of California Walnuts on Cardiovascular Health Phase 1
Completed NCT00858728 - Effect of Fruit and Vegetable Consumption on Immune Function in the Elderly N/A
Recruiting NCT06379282 - Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia N/A
Active, not recruiting NCT03442348 - Omega 3 and Fibre Intervention Study to Improve Metabolic Health N/A
Completed NCT04486144 - Impact Nerium Oleander on Immune Function N/A
Completed NCT05510050 - Comparison Study of Manapol and DaltonMax on Immune Function, Microbiome, and Related Variables in Men and Women N/A
Completed NCT01586247 - The Effect of a Prebiotic, Probiotic and Synbiotic on the Gut Microbiota and Immune Response of Older Volunteers (GOS) N/A
Completed NCT05297825 - Twins Nutrition Study (TwiNS): Vegan vs. Omnivore N/A
Recruiting NCT06325969 - PCOS Patients Immune Status Evaluation
Recruiting NCT06325956 - PCOS Immune Function Predicts Metformin Efficacy N/A
Completed NCT03690999 - The RAMP Study - Rejuvenation of the Aging Microbiota With Prebiotics N/A
Recruiting NCT04741308 - Cognitive Behavior Therapy (CBT) and Psychological Status and Immune Function N/A
Completed NCT02261961 - Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults N/A
Completed NCT03330392 - Evaluation of Efficacy and Safety of AGP on Immune Enhancement N/A
Recruiting NCT06203249 - Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Recruiting NCT05632341 - GCWB1176 Evaluates the Effectiveness and Safety of Immune Function N/A
Completed NCT03718988 - SWAP-MEAT: Study With Appetizing Plant Food - Meat Eating Alternatives Trial N/A